The story has been updated to include comments from NeoGenomics' conference call on Tuesday. 

NEW YORK (GenomeWeb) – NeoGenomics today reported a 5 percent year-over-year rise in revenues for the second quarter, driven by strong growth in clinical genetic testing.

For the three months ended June 30, the Fort Myers, Florida-based cancer genetic testing firm recorded $66.1 million in total revenues, up from $63.1 million in the year-ago period and beating the consensus Wall Street estimate of $63.0 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.